Cobamamide
As of the edition of 20 October 2026, Cobamamide is a drug: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Unknown
- Brand name
- B12 Jaba
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Bouchara Recordati; 3 holders in all
- Registered trials
- 2, 0 stopped early
- Disease areas
- Immune system; Inherited and neonatal; Nutrition and metabolism; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| HanAll BioPharma | Lead sponsor of trials | 2012 to now |